subject: Monoclonal Antibodies: 2010 - Market Research Report On Aarkstore Enterprise [print this page] Introduction Introduction
Across the branded prescription pharmaceutical market monoclonal antibodies (MAbs) are forecast to be the strongest performing molecule type, delivering a forecast six year compound annual growth rate of 9.5% over 2009-15, outpacing the growth rates of small molecules, therapeutic proteins and vaccines. As a result, there is a strong correlation between a strong MAbs portfolio and overall company
Features and benefits
Strategic dynamics within the sector are broken down by product, company, geography, therapy area, technology type and target.
The outlook for the sector is compared with other sectors of the pharmaceutical industry: small molecules, therapeutic proteins and vaccines.
The impact of biosimilars on future MAb sales growth is evaluated and compared with small molecule brand sales following genericization
Highlights
While Datamonitor believes biosimilar MAbs will make it onto the major markets, the rate of sales erosion of such a biosimilar MAb will be far less than that experienced by a small molecule upon generic entry.
Your key questions answered
Assess the outlook for the monoclonal antibodies sector through to 2015
Evaluate the impact of monoclonal antibody on company performances across the PharmaVitae universe
Appraise the technological developments being made in the sector and see where monoclonal antibody pipelines are being focussed
Table of Contents :
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this Sector Report 3
PharmaVitae Explorer database 3
Chapter structure 3
Data sourcing 4
Chapter 2 Executive Summary 5
Key findings 5
Introduction to the PharmaVitae company universe 7
The prescription pharmaceutical market to 2015 9
The MAb market will deliver the largest and fastest sales growth across the industry 15
The MAb sector will remain the fastest growing across the pharmaceutical industry 22
Historical market analysis 23
Forecast market analysis 26
Chapter 3 MAb Technology Overview 40
Key findings 40
Introduction 41
Monoclonal antibodies as therapeutic agents 43
Evolution of MAbs 47
Antibody drug conjugates an alternative combination therapy 55
Bispecific antibodies is now the time for commercial success? 57
Trifunctional antibodies successful innovation in a niche indication 58
Ablynxs nanobodies 59
GSKs acquisition of Domantis gives it ownership of DAbs will the leading Big Pharma player in inhalable drug delivery echo this into the antibody market? 60
